(NYSE:FCN), WASHINGTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Joshua Baca as a Senior Managing Director. Mr. Baca, who is based in Washington, D.C., joins FTI Consulting's Strategic Communications segment with more than 20 years of experience at the intersection of government, business and reputation. In […]

(TSX:AGF-B),(TSX:AGF.B),(TSX:AGFB),(TSX:AMGR),(TSX:AGSL), TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) announced today the launch of ETF series units for AGF American Growth Fund and AGF Global Select Fund, providing investors with access to legacy funds with long-standing, proven track records in an ETF series. “This launch expands our ETF lineup and responds

Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 GlobeNewswire January 08, 2026 Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer

Alveus Therapeutics Launches with $160 Million Series A Financing to Advance Next-Generation Therapies for Obesity and Metabolic Diseases GlobeNewswire January 08, 2026 Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management

ZenaTech Completes 20th Acquisition in Year One of Drone as a Service, Strengthening California Wildfire Management and Public Works Opportunities GlobeNewswire January 08, 2026 VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ(TM) for Leptomeningeal Metastases On track to define optimal dosing interval and advance manufacturing scale up of REYOBIQ for pivotal trial readiness in late 2026 GlobeNewswire January 08, 2026 HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Plus

Electra Provides Update on Refinery Project Progress GlobeNewswire January 08, 2026 TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”), a leader in advancing North America's critical minerals processing, is pleased to provide an update on construction progress at North America's first cobalt sulfate refinery.

North American Niobium and Critical Minerals Corp. Reports Positive Preliminary Soil-Gas Radon Survey Results at Blanchette and Bardy; Phase 2 Planned with Rapid Follow-Up Portable Bedrock Drilling Program GlobeNewswire January 08, 2026 Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North

ElevateBio Achieves Sixth Consecutive Year of Revenue Growth Driven by Expansion of its Genetic Medicine Technology and Manufacturing Business GlobeNewswire January 08, 2026 – Achieved 98% manufacturing batch success rate at BaseCamp across cell therapy, viral vector, and mRNA – Positioned U.S.-based biomanufacturing hub to supply genetic medicine products across North America, South America, Europe,

Atsena Completes Dosing in Part B of the Phase I/II/III LIGHTHOUSE Trial Evaluating ATSN-201 to Treat X-linked Retinoschisis and Announces Plans for Initiation of Pivotal Part C Cohort GlobeNewswire January 08, 2026 Enrollment of pivotal cohort expected to begin in Q1 2026; ATSN-201 BLA submission on track for early 2028 DURHAM, N.C., Jan. 08, 2026